STAT+: Microbiome therapy companies face the fallout of failed Seres trial

A frost may be setting in across the microbiome therapeutics space after another clinical trial failure announcement from Seres Therapeutics, this time with an ulcerative colitis treatment.

Not only has Seres’ share price has fallen more than 60% since Thursday, the stock prices of rival microbiome therapy makers Finch Therapeutics, Evelo Biosciences, and Kaleido Biosciences were down by roughly 20%.

Continue to STAT+ to read the full story…

STAT+: Microbiome therapy companies face the fallout of failed Seres trial

Leave a Reply

Your email address will not be published. Required fields are marked *

Scroll to top